INSM Insmed Inc

Insmed Inc. (Nasdaq:INSM) today announced that it will release its 2007 first quarter results before the market opens on Thursday, May 10, 2007. Management will host an investment community conference call beginning at 11:00 a.m. (ET) to discuss the financial results, provide a business update and answer questions. Individuals interested in listening to the live conference call may do so by dialing 866-558-6338 toll free within the U.S. and Canada, or 213-785-2437 for international callers. A telephone replay will be available approximately two hours after the call for two weeks by dialing 866-245-6755 from the U.S., or 416-915-1035 for international callers. The passcode is 270068. Individuals interested in listening to the conference call via the Internet may do so by visiting www.insmed.com. A replay will be available on the Company�s Web site for 90 days. About Insmed Insmed is a biopharmaceutical company focused on the development and approval of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. Forward Looking Statements Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding planned clinical study design, our regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates, the FDA may interpret the results of our studies differently than we have, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.